The anti-proliferative activity of tovorafenib and TAK-632 was evaluated by CTG cell viability assay at 72 hours after treatment in the NF1-LOF tumor cell lines and the BRAF V600E tumor cell line, A375. This evidence concerns the gene BRAF and neoplasm.